AIMS: To determine changes in the availability of medicines for children in Australia and to determine the status of newly introduced chemical entities by age category. METHODS: Using the Australian Prescription Products Guide and the Schedule of Pharmaceutical Benefits, licensed medicines available in Australia in the calendar years 1998 and 2002 were examined. RESULTS: The total number of medicines licensed in Australia increased from 1544 to 1903, the number of licensed paediatric items increased from 579 (37.5%) to 725 (38.1%), and those both licensed for paediatric use and subsidized increased from 356 (23.1%) to 441 (23.2%). The number of medicines with formulations suitable for paediatric use increased from 861 (55.7%) to 967 (50.8%), and of these 382 (24.7%) and 466 (24.5%) were licensed for paediatric use. Of the 90 new orally available chemical entities licensed for adults only 12 (13%) were licensed for children. Three (3%) were licensed for the 0-28 days and 28 days to 23 months age groups, eight (9%) for 2-11 years and 12 (13%) for 12-18 years. An additional 14 orally available chemical entities previously only licensed for adults, were licensed for children by 2002. CONCLUSIONS: There have been some improvements in medicines licensing for older children, but not for children under the age of two years.
AIMS: To determine changes in the availability of medicines for children in Australia and to determine the status of newly introduced chemical entities by age category. METHODS: Using the Australian Prescription Products Guide and the Schedule of Pharmaceutical Benefits, licensed medicines available in Australia in the calendar years 1998 and 2002 were examined. RESULTS: The total number of medicines licensed in Australia increased from 1544 to 1903, the number of licensed paediatric items increased from 579 (37.5%) to 725 (38.1%), and those both licensed for paediatric use and subsidized increased from 356 (23.1%) to 441 (23.2%). The number of medicines with formulations suitable for paediatric use increased from 861 (55.7%) to 967 (50.8%), and of these 382 (24.7%) and 466 (24.5%) were licensed for paediatric use. Of the 90 new orally available chemical entities licensed for adults only 12 (13%) were licensed for children. Three (3%) were licensed for the 0-28 days and 28 days to 23 months age groups, eight (9%) for 2-11 years and 12 (13%) for 12-18 years. An additional 14 orally available chemical entities previously only licensed for adults, were licensed for children by 2002. CONCLUSIONS: There have been some improvements in medicines licensing for older children, but not for children under the age of two years.
Authors: Reinhild Bücheler; Matthias Schwab; Klaus Mörike; Bernhard Kalchthaler; Hartmut Mohr; Helmut Schröder; Peter Schwoerer; Christoph H Gleiter Journal: BMJ Date: 2002-06-01
Authors: S Conroy; I Choonara; P Impicciatore; A Mohn; H Arnell; A Rane; C Knoeppel; H Seyberth; C Pandolfini; M P Raffaelli; F Rocchi; M Bonati; G Jong; M de Hoog; J van den Anker Journal: BMJ Date: 2000-01-08
Authors: M Chalumeau; J M Tréluyer; B Salanave; R Assathiany; G Chéron; N Crocheton; C Rougeron; M Mares; G Bréart; G Pons Journal: Arch Dis Child Date: 2000-12 Impact factor: 3.791
Authors: Diana A van Riet-Nales; Karin E de Jager; Alfred F A M Schobben; Toine C G Egberts; Carin M A Rademaker Journal: Br J Clin Pharmacol Date: 2011-09 Impact factor: 4.335